Monoclonal antibody, method of production thereof and use thereof
CA 2072412 A1 · Owner: Takeda Chemical Industries, Ltd. · Inventors: Katsuno, Makoto; Kondo, Koichi; Kobayashi, Takahisa
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
Disclosed are a monoclonal antibody which specifically recognizes 6,15-diketo-13,14-dihydro-prostaglandin F1.alpha. with high sensitivity, a hybridoma producing the monoclonal antibody a, method of preparing the hybridoma and an immunoassay method for 6,15-diketo-13,14-dihydro-prostaglandin F1.alpha. using the monoclonal antibody. The monoclonal antibody makes it possible to conveniently measure with specificity and high sensitivity 6,15diketo-13,14-dihydro-prostaglandin F1.alpha. that is a stable metabolite of prostaglandin I2. The monoclonal antibody is useful in determining the content of prostaglandin I2 which, exhibits platelet aggregating inhibitory activity vasodilating, activity and …
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed June 25, 1992. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended June 25, 2012.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by June 25, 2014.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.